Outcome MeasureSubstance Use

QSU

Questionnaire of Smoking Urges

2 Papers in Blossom

Outcome Data Across Studies

Reported results for QSU across 1 study with quantitative data.

Outcome data across 2 study arm–timepoint observations
SD
Effects of a Single Sub-Anesthetic Dose of Ketamine in Tobacco Use Disorder: An Active-Placebo, Randomized Crossover Study
2026Secondary
Ketamine(experimental)11843.618.40.830
Effects of a Single Sub-Anesthetic Dose of Ketamine in Tobacco Use Disorder: An Active-Placebo, Randomized Crossover Study
2026Secondary
Midazolam(experimental)11844.513.80.830

Papers Using QSU

Open Accessindividual

Effects of a Single Sub-Anesthetic Dose of Ketamine in Tobacco Use Disorder: An Active-Placebo, Randomized Crossover Study

This randomised crossover study (n=18) tested a single sub-anesthetic ketamine infusion against midazolam in adults with tobacco use disorder who were not trying to quit smoking. Ketamine was well tolerated but did not clearly reduce smoking, craving or withdrawal, although some participants reported stronger psychological effects and found abstaining easier afterwards.

Published
Journal
Brain Sciences
Authors
Luzum, N. R., McCall, M. H., Talley Boyd, C., Columbano, H., Ip, E., Saldana, S., Oliveto, A. H., Addicott, M.
Open Accessindividual

Psilocybin or Nicotine Patch for Smoking Cessation A Pilot Randomized Clinical Trial

This pilot randomised clinical trial (n=82) found that a single dose of psilocybin (30mg/70kg) combined with cognitive behavioural therapy produced significantly higher long-term smoking abstinence rates at 6 months compared to nicotine patches plus CBT (41% vs 10%), with no serious adverse events attributed to either treatment.

Published
Journal
JAMA Network Open
Authors
Johnson, M. W., Naudé, G. P., Hendricks, P. S., Garcia-Romeu, A.

Quick Facts

Full Name
Questionnaire of Smoking Urges
Domain
Substance Use
Papers Indexed
2
Score Range
10–70
Interpretation
Lower = better
Unit
points
All Measures